ClinicalTrials.gg
CompletedNCT07344233Updated Oct 21, 2026Results posted

Neurofeedback During Naturalistic Stimuli to Reduce Craving in Heroin Addiction

An interventional study of Real-time fMRI Neurofeedback and Sham Real-time fMRI Neurofeedback in Opioid Use Disorder, Substance Use Disorder and Heroin Use Disorder, sponsored by Icahn School of Medicine at Mount Sinai. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled May 2025, registered Jan 2026).
Updated Oct 21, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Enrollment
723rd of 1,098
28 · median 56
Started
2025
with 88 others
No phase
571 of 1,223
133 open now
Registered
1,163rd of 1,223
by date

Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 723rd largest by enrollment of the 1,098 interventional ones that give a count, is one of 89 that started in 2025, is one of 571 with no phase, and was the 1,163rd registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

241 more — sign in →

All 246 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,223 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

Support groups are an important component of addiction treatment, where individuals at more stable stages of their recovery help others by sharing personal experiences. This phenomenon suggests that the brain states of individuals further along in their recovery process may be useful in guiding those who are at an earlier stage. In this project, the researchers will test this idea and develop a personalized therapeutic tool based on real-time fMRI neurofeedback, whereby individuals with heroin use disorder (iHUD) early in treatment will learn to modulate their own brain state to more closely align with iHUD who are at later stages of treatment. Specifically, iHUD exhibit heightened reactivity to naturalistic drug cues in brain networks underlying salience attribution, reward processing, executive function and others. This fMRI brain hyperactivity pattern is reduced, concomitant with craving reductions, with about 3 months of inpatient treatment. In this neurofeedback project, iHUD who are beginning treatment will view naturalistic drug cues and receive feedback about how similar their brain activity is to the target recovery pattern, learning to modulate their own brain activity to reduce drug cue reactivity and craving. This study will offer insights into the mechanisms of recovery in addiction, particularly as coordinated across individuals with shared experience and goals. If successful, the neurofeedback-based training may lead to new brain-based and personalized tools for recovery in this devastating disorder.

03

Conditions studied

  • Opioid Use Disorder
  • Substance Use Disorder
  • Heroin Use Disorder
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand, give and perform the tasks
  • males and females 18-64 years of age at the time of enrollment in the study
  • diagnosis of opioid use disorder with heroin as the primary drug of choice
  • currently enrolled in a treatment facility for heroin use as the primary concern
  • 2-4 week abstinence from non-prescribed opioid use/stabilized on medication assisted therapy (MAT) using either methadone and/or buprenorphine.

Exclusion criteria

Exclusion criteria:

  • present or past history of a neurodevelopmental, neurological, or a psychotic disorder
  • head trauma with loss of consciousness for more than 30 min
  • use of medications (current or in the last 6 months) with known CNS effects which may alter cerebral function, with the exception of psychotropics for the treatment of pain/depression/anxiety/PTSD (e.g. SSRIs) or as otherwise determined by the Principle Investigator
  • current medical illness and/or evident infection
  • being pregnant or nursing
  • to the MRI environment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Real Neurofeedback

    Participants receive real-time fMRI neurofeedback reflecting their own brain activity during a drug-related movie.

    Behavioral: Real-time fMRI Neurofeedback

  • Sham comparator
    Sham (yolked) Neurofeedback

    Participants receive sham real-time fMRI neurofeedback yoked to a matched participant and unrelated to their own brain activity.

    Behavioral: Sham Real-time fMRI Neurofeedback

Interventions

  • BehavioralReal-time fMRI Neurofeedback

    Real-time feedback reflecting the similarity between participant's brain activity patterns and a predefined target while viewing a drug-related movie.

  • BehavioralSham Real-time fMRI Neurofeedback

    Real-time feedback yoked to another participant and not reflective of the participant's own brain activity.

06

What researchers measure

Primary outcomes

  1. Cue/Movie-induced Craving Score

    Self-reported ratings of heroin craving on a 0-9 point scale, with higher scores indicating higher craving.

    Time frame: Immediately before and immediately after neurofeedback procedure (average 17 min MRI scan)

Secondary outcomes

  1. Neurofeedback Score Change

    Change in neurofeedback performance, reflecting participants' ability to modulate brain activity toward the predefined target pattern. Neurofeedback scores range 0-100, with higher scores indicating more similar brain activity to the target pattern.

    Time frame: During each 20 minute neurofeedback training session. Participants complete 8 neurofeedback sessions over the course of 4 consecutive days.

07

Results

Posted Oct 21, 2026

Participant flow

Participant flow — Overall Study
MilestoneReal NeurofeedbackSham (Yolked) Neurofeedback
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryCue/Movie-induced Craving Score

Self-reported ratings of heroin craving on a 0-9 point scale, with higher scores indicating higher craving.

Time frame:
Immediately before and immediately after neurofeedback procedure (average 17 min MRI scan)
Reported as:
Mean · score on a scale
Cue/Movie-induced Craving Score
score on a scaleReal NeurofeedbackSham (Yolked) Neurofeedback
Day 1, immediately pre neurofeedback treatment, run 13.0 ± 2.754.60 ± 2.59
Day 1, immediately post neurofeedback treatment, run 11.60 ± 2.464.60 ± 3.03
Day 1, immediately pre neurofeedback treatment, run 21.78 ± 2.544.70 ± 3.53
Day 1, immediately post neurofeedback treatment, run 21.11 ± 1.973.80 ± 3.52
Day 2, immediately pre neurofeedback treatment, run 11.22 ± 2.173.50 ± 3.31
Day 2, immediately post neurofeedback treatment, run 11.00 ± 2.294.00 ± 3.20
Day 2, immediately pre neurofeedback treatment, run 21.33 ± 2.242.80 ± 3.36
Day 2, immediately post neurofeedback treatment, run 21.11 ± 1.973.60 ± 3.34
Day 3, immediately pre neurofeedback treatment, run 11.80 ± 2.104.30 ± 3.30
Day 3, immediately post neurofeedback treatment, run 10.70 ± 1.344.00 ± 3.30
Day 3, immediately pre neurofeedback treatment, run 20.80 ± 1.323.80 ± 3.19
Day 3, immediately post neurofeedback treatment, run 20.50 ± 0.973.70 ± 3.50
Day 4, immediately pre neurofeedback treatment, run 11.30 ± 1.833.70 ± 3.20
Day 4, immediately post neurofeedback treatment, run 10.50 ± 1.083.00 ± 3.59
Day 4, immediately pre neurofeedback treatment, run 21.30 ± 1.703.00 ± 3.39
Day 4, immediately post neurofeedback treatment, run 20.90 ± 1.732.78 ± 3.49
SecondaryNeurofeedback Score Change

Change in neurofeedback performance, reflecting participants' ability to modulate brain activity toward the predefined target pattern. Neurofeedback scores range 0-100, with higher scores indicating more similar brain activity to the target pattern.

Time frame:
During each 20 minute neurofeedback training session. Participants complete 8 neurofeedback sessions over the course of 4 consecutive days.

Results for this outcome have not been posted.

Adverse events

Collected over From enrollment until end of last study visit, up to 10 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Real Neurofeedback0/10 (0%)0/10 (0%)0/10 (0%)
Sham (Yolked) Neurofeedback0/10 (0%)0/10 (0%)0/10 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Real NeurofeedbackSham (Yolked) NeurofeedbackTotal
Mean44 ± 1141 ± 743 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Real NeurofeedbackSham (Yolked) NeurofeedbackTotal
Female101
Male91019
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Real NeurofeedbackSham (Yolked) NeurofeedbackTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American224
White6511
More than one race235
Unknown or Not Reported000
Education
Education(Years)Real NeurofeedbackSham (Yolked) NeurofeedbackTotal
Mean12.80 ± 1.9310.90 ± 2.1811.80 ± 2.25
08

Study locations

1 site
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol

Time frame: Immediately following publication. No end date.

Access criteria: Researchers who provide a methodologically sound proposal. Any purpose. Specify Other Mechanism Researchers who provide a methodologically sound proposal. Any purpose. Proposals should be directed to NARC@mssm.edu. To gain access, data requestors will need to sign a data access agreement.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Aug 2025, 3 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's 3 months is below that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jan 15, 2026
StartActual
May 20, 2025
Primary completionActual
Aug 31, 2025
CompletionActual
Aug 31, 2025
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedCue/movieMovie-induced craving scoreCraving ScoreTime frame: Immediately before and immediately after neurofeedback procedure → Immediately before and immediately after neurofeedback procedure (average 17 min MRI scan)
Oct 21, 2026
Documents
Show all 1 update
  1. Oct 21, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedCue/movieMovie-induced craving scoreCraving ScoreTime frame: Immediately before and immediately after neurofeedback procedure → Immediately before and immediately after neurofeedback procedure (average 17 min MRI scan)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07344233
Responsible party
Rita Goldstein (Professor of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Jan 15, 2026
Start date
May 20, 2025
Primary completion
Aug 31, 2025
Completion
Aug 31, 2025
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

Rita Goldstein, PhD
principal investigator · NARC@mssm.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion